Triple Antibiotic Ointment
NDC Package 84722-3032-0
Package Information
Triple Antibiotic (bacitracin zinc, neomycin sulfate, polymyxin b sulfate) ointment is classified as a
- aminoglycoside antibacterial - [epc] (established pharmacologic class)
- aminoglycosides - [cs]
- decreased cell wall synthesis & repair - [pe] (physiologic effect)
- polymyxin-class antibacterial - [epc] (established pharmacologic class)
- polymyxins - [cs]
- aminoglycoside antibacterial - [epc] (established pharmacologic class)
- aminoglycosides - [cs]
- decreased cell wall synthesis & repair - [pe] (physiologic effect)
- polymyxin-class antibacterial - [epc] (established pharmacologic class)
- polymyxins - [cs]
Identification & Billing
- RxCUI: 204602 - bacitracin 400 UNT / neomycin 3.5 MG / polymyxin B 5000 UNT per GM Topical Ointment
- RxCUI: 204602 - bacitracin 0.4 UNT/MG / neomycin 0.0035 MG/MG / polymyxin B 5 UNT/MG Topical Ointment
- RxCUI: 204602 - bacitracin 400 UNT / neomycin 3.5 MG (as neomycin sulfate 5 MG) / polymyxin B 5000 UNT per GM Topical Ointment
Clinical Specifications
- Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
- Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
- Aminoglycoside Antibacterial - [EPC] (Established Pharmacologic Class)
- Aminoglycosides - [CS]
- Decreased Cell Wall Synthesis & Repair - [PE] (Physiologic Effect)
- Polymyxin-class Antibacterial - [EPC] (Established Pharmacologic Class)
- Polymyxins - [CS]
- Aminoglycoside Antibacterial - [EPC] (Established Pharmacologic Class)
- Aminoglycosides - [CS]
- Decreased Cell Wall Synthesis & Repair - [PE] (Physiologic Effect)
- Polymyxin-class Antibacterial - [EPC] (Established Pharmacologic Class)
- Polymyxins - [CS]
Regulatory & Marketing
Hierarchy Structure
- 84722 - Vive Health Llc
- 84722-3032 - Triple Antibiotic
- 84722-3032-0 - 144 OINTMENT in 1 PACKET
- 84722-3032 - Triple Antibiotic
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (84722-3032). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 84722-3032-0 identifies a specific commercial package of 144 ointment in 1 packet of Triple Antibiotic, a human over the counter drug labeled by Vive Health Llc. This ointment is formulated for topical use and contains bacitracin; neomycin; polymyxin b as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Vive Health Llc on October 01, 2024. The current certification is valid through December 31, 2026.
How is this Vive Health Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 84722303200. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.